Mucopolysaccharidosis Type III
文献摘要
Clinical characteristics Mucopolysaccharidosis type III (MPS III) is a multisystem lysosomal storage disease characterized by progressive central nervous system degeneration resulting in severe intellectual disability, developmental regression, behavioral problems, and sleep disturbances. Four MPS III subtypes are distinguished by the deficient enzyme. Neurologic decline occurs in all affected individuals; however, clinical severity varies widely within and among the four subtypes and even among members of the same family. Disease onset and progression range from the more typical early-onset, rapidly progressive form with death in late childhood or adolescence to less common slowly progressive forms with later childhood or rare adult onset and survival into adulthood. Systemic manifestations can include hearing impairment, recurrent ear, nose, and throat (ENT) and upper respiratory tract infections, cardiac disease (valvular thickening and valvular dysfunction), hepatosplenomegaly, and musculoskeletal manifestations (dysostosis multiplex, joint stiffness, scoliosis, and femoral osteonecrosis). Death usually occurs in the second or third decade of life secondary to neurologic disease or respiratory tract infections. Diagnosis/testing The diagnosis of MPS III is established in an individual with suggestive clinical and laboratory findings (elevated urinary glycosaminoglycans, predominantly heparan sulfate) in whom either biallelic pathogenic variants in one of four genes (GNS, HGSNAT, NAGLU, and SGSH) and/or deficiency of the respective lysosomal enzyme have been identified. Management Targeted therapy: Rebisufligene etisparvovec-hopf is a gene therapy approved for children with MPS III caused by pathogenic variants in SGSH with preserved neurodevelopmental function. Supportive care: Developmental support; pharmacologic management of psychiatric/behavioral issues; anti-seizure medication per neurologist; management of visual impairment as prescribed by consulting specialists; consider melatonin or other medication for sleep issues; otolaryngology evaluation for sleep apnea; standard treatments for recurrent ENT and upper respiratory tract infections and hearing impairment; management of cardiac involvement as prescribed by consulting specialists; management of feeding difficulties and malnutrition; gastrostomy tube placement when indicated; physical therapy and/or orthopedic management of musculoskeletal manifestations; vitamin D therapy in individuals with vitamin D deficiency; creation of a physically safe environment at home; family and social work support; palliative care per palliative care specialist. Evaluation for participation in ongoing clinical trials of investigational therapies (e.g., gene therapy, enzyme replacement therapy) is recommended given the rapidly evolving treatment landscape. Surveillance: Regularly monitor developmental capabilities and educational needs; assess behavioral issues and sleep disturbance and evaluate need for or efficacy of pharmacologic treatment; assess need for or efficacy of anti-seizure medication as indicated; perform regular ophthalmologic, dental, hearing, and respiratory assessments; polysomnography as needed; perform regular echocardiogram and EKG; regularly assess swallowing, feeding, digestion, nutritional status, and musculoskeletal manifestations; perform regular laboratory testing including full blood count, electrolytes, liver function tests, and serum vitamin D. In individuals with pain, distress, and unexplained behavioral issues perform a detailed exam, medical history, laboratory studies, and clinical and imaging assessment for potential neurologic, dental, ENT, abdominal, and orthopedic causes. Agents/circumstances to avoid: Procedures requiring anesthesia in centers ill-equipped or inexperienced in caring for individuals with complex airway management issues; orthopedic surgery without individualized consideration of disease stage, perioperative burden, and likely benefit; environments not adapted to minimize risk from unpredictable behaviors. Evaluation of relatives at risk: Clarify the genetic status of apparently asymptomatic older and younger at-risk sibs of an affected individual in order to identify as early as possible those who would benefit from prompt initiation of supportive interventions, participation in clinical trials, or disease-specific therapies that may become available. Genetic counseling MPS III is inherited in an autosomal recessive manner. If both parents are heterozygous for a pathogenic variant in GNS, HGSNAT, NAGLU, or SGSH, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the MPS III-causing pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible.